Technology Overview – Why RAPID RHINO Products?

Technology Overview – Why RAPID RHINO Products?2018-05-17T15:25:56+00:00
wetleafright

CMC–Part of our daily lives.

CMC is a widely used, multipurpose additive that is found in many products that consumers come into contact with on a daily basis, from food to cosmetics and lotions. It is also reassuring to know that as a food additive, CMC has a GRAS (generally recognized as safe) rating by the FDA.2

Welcome CAEP Members!

To place an order or get more information, contact us

2280 Argentia Road
Mississauga, Ontario
L5N 6H8
Customer Service Tel: 877 977-1772

Or click the button below.

Get RAPID RHINO Information

CMC Technology – Available exclusively in RAPID RHINO ENT Products.

Only Smith & Nephew offers the RAPID RHINO portfolio with an exclusive formulation of CarboxyMethyl Cellulose (CMC), a plant-derived material. When mixed with water, it forms a cushioning hydrocolloid gel that naturally drains from the body after several days.

Natural CMC Technology offers multiple patient care advantages, giving healthcare professionals the utmost confidence as it:

  • Helps minimize bleeding and edema during surgery – designed to minimize intra- and post-op oozing
  • Fills space and acts as a moist physical barrier between mucosal surfaces to prevent painful
    adhesions after surgery or trauma
  • Is not associated with hypersensitivity in patients

All strong reasons to make RAPID RHINO products with CMC Technology your first choice.

noses

The right fit, no matter what size anatomy

  • Ultra low profile design provides unsurpassed ease of insertion and quickly conforms to nasal anatomy1
  • Provides gentle and even compression to areas of epistaxis
  • Designed to prevent adherence to tissue or blood clots upon removal
  • Unilateral and bilateral options with or without an airway
  • Fits both large and small patient anatomy

References

  1. Singer AJ, Blanda M, Cronin K, LoGiudice-Khwaja M, Gulla J, Katz A. Comparison of nasal tampons for the treatment of epistaxis in the emergency room department: a randomized controlled trial. Ann Emerg Med. 2005; 45(2):134-139
  2. Cooper, Monica. CMC Considerations for 505(b)(2) Applications. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C. October 2011. Retreived from: http://www.fda.gov/downloads/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm301043.pdf